Security Snapshot

Monopar Therapeutics - Common Stock (MNPR) Institutional Ownership

CUSIP: 61023L207

13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

82

Shares (Excl. Options)

6,235,981

Price

$54.79

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock
Symbol
MNPR on Nasdaq
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
6,235,981
Latest holder snapshot 5 signals
Total 13F value
$341,548,688
Portfolio coverage rank
0%
Share change
+708,358
Value change
+$37,301,460
Number of holders
82
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
6,646,654
SEC-reported price per share
$61.44
Insider filing price
$61.44
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • MNPR - Monopar Therapeutics - Common Stock is tracked under CUSIP 61023L207.
  • 82 institutions reported positions in Q1 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 74 to 82 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $360,987,109 to $341,548,688.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 82 institutions filings for Q1 2026.

Open SEC evidence

Security key

61023L207

Latest holder period

Q1 2026

13F holders

82

13D/G owners

6

CIK / CUSIP context first

Open Q1 2026 holders MNPR full holder history Monopar Therapeutics SEC filings Monopar Therapeutics company facts Monopar Therapeutics insider transactions Monopar Therapeutics 13D/G history

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
MNPR
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 20% +1.6% $105,138,701 +$9,391,992 1,287,368 +9.8% JANUS HENDERSON GROUP PLC 30 Sep 2025
Monopar Therapeutics 13% $31,414,229 704,829 Hendricks Diane 09 Dec 2024
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $43,402,756 -$4,890,637 667,632 -10% RA Capital Management, L.P. 31 Dec 2025
ASTRAZENECA PLC 7.8% $34,126,392 522,667 AstraZeneca PLC 31 Dec 2025
Adage Capital Management, L.P. 6.2% -36% $23,788,856 -$9,814,000 424,195 -29% Adage Capital Management, L.P. 31 Mar 2026
Saturn V Capital Management LP 5.2% $19,382,706 345,626 Saturn V Capital Management LP 05 Jan 2026

As of 31 Mar 2026, 82 institutional investors reported holding 6,235,981 shares of Monopar Therapeutics - Common Stock (MNPR). This represents 94% of the company’s total 6,646,654 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
85%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 20% 1,317,410 0% 0.03% $72,062,327
RA CAPITAL MANAGEMENT, L.P. 10% 667,207 0% 0.39% $36,556,272
Saturn V Capital Management LP 5.2% 345,626 +6.1% 3.4% $18,936,849
DEERFIELD MANAGEMENT COMPANY, L.P. 4.9% 323,745 +90% 0.21% $17,737,989
BlackRock, Inc. 4.8% 316,567 +24% 0% $17,344,705
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.7% 309,195 -52% 0.03% $16,940,794
Siren, L.L.C. 4.1% 270,118 +27% 0.41% $14,799,765
ADAR1 Capital Management, LLC 4% 264,278 +13% 0.88% $14,479,792
Polar Capital Holdings Plc 3.4% 226,526 +114% 0.05% $12,411,360
VANGUARD CAPITAL MANAGEMENT LLC 3.3% 218,463 0% 0% $11,969,588
WELLINGTON MANAGEMENT GROUP LLP 2.6% 174,342 -23% 0% $9,552,198
Sio Capital Management, LLC 2.6% 173,506 1.4% $9,506,394
Balyasny Asset Management L.P. 2.1% 136,443 +328% 0.01% $7,475,712
TCG Crossover Management, LLC 2% 132,103 -6.9% 0.21% $7,237,923
Alyeska Investment Group, L.P. 1.5% 100,000 +150% 0.02% $5,479,000
GEODE CAPITAL MANAGEMENT, LLC 1.5% 99,918 +0.92% 0% $5,476,049
Vivo Capital, LLC 1.4% 90,500 0% 0.41% $4,958,495
STATE STREET CORP 1.3% 88,355 +5.2% 0% $4,840,970
Bank of New York Mellon Corp 1.2% 78,618 +21% 0% $4,307,490
Vestal Point Capital, LP 0.98% 65,418 0.1% $3,584,252
Walleye Capital LLC 0.95% 63,119 0.02% $3,458,290
BANK OF AMERICA CORP /DE/ 0.9% 59,699 +838% 0% $3,270,908
CITADEL ADVISORS LLC 0.88% 58,436 +1052% 0% $3,201,708
MILLENNIUM MANAGEMENT LLC 0.8% 52,951 -31% 0% $2,901,185
PRICE T ROWE ASSOCIATES INC /MD/ 0.72% 47,702 +110% 0% $2,614,000

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
7
Latest
Q1 2026
Rows shown
1-7 of 7
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 6,235,981 $341,548,688 +$37,301,460 $54.79 82
2025 Q4 5,529,904 $360,987,109 +$75,159,494 $65.30 74
2025 Q3 4,336,026 $354,298,233 +$99,764,618 $81.67 55
2025 Q2 3,176,497 $113,304,454 +$10,313,028 $35.78 43
2025 Q1 2,886,019 $109,374,138 +$11,536,779 $36.41 34
2024 Q4 2,578,295 $57,125,546 +$56,777,792 $22.00 18
2024 Q3 15,707 $105,865 +$105,865 $6.74 6
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .